Sorrento Therapeutics Inc. buy tamam

SRNE has some earlier stage compounds in its pipeline targeting Immuno-Oncology and Pain Management.

Oppenheimer's analyst had this to say about his positive view on Sorrento:
"On Wednesday, Sorrento’s subsidiary SCILEX Pharmaceuticals received FDA approval under a 505(B)(2)

for ZTlido, a lidocaine adhesive patch intended for the treatment ofshingles-related pain. The approval shows SCILEX’s persistence with regulators has paid off; in 2016, ZTlido received a complete response letter citing deficiencies in equivalency testing and CMC. We view ZTlido as a key pillar in Sorrento’s strategy of hedging high-risk early stage programs with lower-risk, cash generating franchises, and we believe the product could provide Sorrento with meaningful sales revenue (estimated peak US+EU ~$220M) to offset operational expenses. With US approval in hand, we expect similar approvals in EU territories could be achieved beginning in late 2018. We reiterate our Outperform rating and increase our PT to $11"

28.06.2018